Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition

A technology of chimeric antibodies and membrane glycoproteins, which can be used in drug combinations, antibodies, blood diseases, etc., and can solve problems such as limiting drug application and failing to improve ischemic symptoms

Active Publication Date: 2014-06-11
苏州苏大赛尔免疫生物技术有限公司 +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these drugs have made great contributions to the improvement of thromboembolic diseases caused by arterial thrombosis, there are still a considerable number of patients who cannot improve ischemic symptoms after using these drugs
In addition, potential bleeding complications limit the use of these drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition
  • Anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition
  • Anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Example 1, the acquisition of anti-human platelet membrane glycoprotein Ibα chimeric antibody:

[0010] 1. Primer design and synthesis,

[0011] The primers involved in the experiment were all synthesized by Invitrogen Company except those provided by the kit.

[0012] HGSP1

GTCCACCTTGGTGCTGCTGGCCGGGTG

KGSP1

ACTTGACATTGATGTCTTTG

HGSP2

GCTGGACAGGGATCCAGAGTTCC

KGSP2

CACGACTGAGGCACCTCCAG

5’RACE Outer Primer

CATGGCTACATGCTGACAGCCTA

5'RACE Inner Primer

CGCGGATCCACAGCCTACTGATGATCAGTCGATG

SZ2HR

GCGGCTAGCCACCATGACATTGAACATGCTG

SZ2HF

GCGGGCCCTTGGTGGAGGCTAAGGAGACGGTGACAG

SZ2KR

GCGATATCATGAGGGTCCTTGCTGAG

SZ2KF

CACCGTACGTTTTATTTTCCAGCTTGGTC

[0013] 2. Cloning and determination of mAb SZ2V region gene,

[0014] Using the total RNA of hybridoma cells secreting the mouse monoclonal antibody SZ2 as a template, the VH and VL genes were cloned using the 5' Rapid Amplif...

Embodiment 2

[0032] Embodiment 2, anti-human platelet membrane glycoprotein Ibα chimeric antibody pharmaceutical composition:

[0033] The present invention also provides a pharmaceutical composition, which contains a pharmaceutically effective amount of anti-human platelet membrane glycoprotein Ibα chimeric antibody pharmaceutical composition and a pharmaceutically acceptable carrier. "Pharmaceutically effective amount" refers to the amount that does not cause adverse, allergic or other adverse reactions to animals or humans when the molecular entities and compositions are administered to animals or humans. "Pharmaceutically acceptable carrier" means that it is compatible with the chimeric antibody of the present invention, that is, it can be blended with it without greatly reducing the effect of the pharmaceutical composition under normal circumstances. Specific examples thereof include sugars: lactose, glucose, sucrose, starches: corn starch, potato starch, cellulose and its derivatives...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition, which comprises a chimeric antibody maturation light chain and a chimeric antibody maturation heavy chain, an amino acid sequence of the chimeric antibody maturation light chain is at 453rd to 666th position from amino acid residues in a sequence 2 in a sequence table, and the amino acid sequence of the chimeric antibody maturation heavy chain is at 1st to 452nd from amino acid residue in the sequence 2 in the sequence table. The invention also discloses a preparation method of the chimeric antibody and a concentration effect analysis.

Description

technical field [0001] The invention relates to the field of biotechnology chimeric antibodies, in particular to an anti-human platelet membrane glycoprotein Ibα chimeric antibody pharmaceutical composition. Background technique [0002] Platelet GPIbα is a platelet-specific membrane glycoprotein that exists in the form of a GPIb-IX-V complex consisting of four subunits, GPIbα, GPIbβ, GPIX, and GPV, in a 2:4:2:1 ratio. proportional composition. They are all type I transmembrane glycoproteins, including extracellular domain, transmembrane domain and cytoplasmic domain. GPIbα and GPIbβ are covalently linked in the form of disulfide bonds to form GPIb, GPIb and GPIX, and GPV is linked in the form of non-covalent bonds to form the GPIb-IX-V complex. GPIbα is the major ligand-binding subunit in this complex. When the blood vessel is damaged, the platelet membrane surface receptor GPIbα binds to the A1 domain of plasma VWF under high shear stress conditions, and at the same tim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395C12N15/12A61P7/02
Inventor 费敏阮长耿杨剑峰
Owner 苏州苏大赛尔免疫生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com